# Un Jung Kang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5253396/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 136 papers | 10,755 citations | 26630 56 h-index | 33894 99 g-index |
| 144 all docs | 144 docs citations | 144 times ranked | 11302 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | DJ-1 and Î±-synuclein in human cerebrospinal fluid as biomarkers of Parkinsonâ€™s disease. Brain, 2010, 133, 713-726. | 7.6 | 575 |
| 2 | A Controlled Trial of Rasagiline in Early Parkinson Disease. Archives of Neurology, 2002, 59, 1937. | 4.5 | 559 |
| 3 | Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology, 2015, 132, 96-168. | 5.7 | 379 |
| 4 | Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology, 2011, 69, 570-580. | 5.3 | 371 |
| 5 | A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543. | 9.0 | 312 |
| 6 | Natural history and treatment of tardive dystonia. Movement Disorders, 1986, 1, 193-208. | 3.9 | 268 |
| 7 | Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. Journal of Neuroscience, 1995, 15, 7810-7820. | 3.6 | 252 |
| 8 | Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Molecular Brain Research, 2003, 114, 123-131. | 2.3 | 235 |
| 9 | Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. European Journal of Neuroscience, 2002, 16, 1829-1838. | 2.6 | 224 |
| 10 | Age-dependent Motor Deficits and Dopaminergic Dysfunction in DJ-1 Null Mice. Journal of Biological Chemistry, 2005, 280, 21418-21426. | 3.4 | 221 |
| 11 | Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience, 1999, 88, 617-628. | 2.3 | 220 |
| 12 | Characterization of PINK1 processing, stability, and subcellular localization. Journal of Neurochemistry, 2008, 106, 464-474. | 3.9 | 216 |
| 13 | Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice. Journal of Neuroscience, 2008, 28, 425-433. | 3.6 | 211 |
| 14 | A Controlled Trial of Rotigotine Monotherapy in Early Parkinson's Disease. Archives of Neurology, 2003, 60, 1721. | 4.5 | 208 |
| 15 | Behavioral models of Parkinson's disease in rodents: A new look at an old problem. Movement Disorders, 2006, 21, 1595-1606. | 3.9 | 200 |
| 16 | Striatal cholinergic interneuron regulation and circuit effects. Frontiers in Synaptic Neuroscience, 2014, 6, 22. | 2.5 | 173 |
| 17 | Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinsonâ€™s disease. Npj Parkinson's Disease, 2018, 4, 11. | 5.3 | 169 |
| 18 | Distant effects of locally injected botulinum toxin: A double-blind study of single fiber EMG changes. Muscle and Nerve, 1991, 14, 672-675. | 2.2 | 167 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Enhanced striatal cholinergic neuronal activity mediates<scp>l</scp>-DOPAâ€“induced dyskinesia in parkinsonian mice. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 840-845. | 7.1 | 166 |
| 20 | Spread of symptoms in idiopathic torsion dystonia. Movement Disorders, 1995, 10, 143-152. | 3.9 | 161 |
| 21 | Plasma-Based Circulating MicroRNA Biomarkers for Parkinson's Disease. Journal of Parkinson's Disease, 2012, 2, 321-331. | 2.8 | 161 |
| 22 | Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy, 2019, 15, 113-130. | 9.1 | 155 |
| 23 | Comparative study of cerebrospinal fluid Î±â€synuclein seeding aggregation assays for diagnosis of Parkinson's disease. Movement Disorders, 2019, 34, 536-544. | 3.9 | 146 |
| 24 | Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus. Neurology, 2007, 69, 427-433. | 1.1 | 143 |
| 25 | Tardive akathisia: An analysis of clinical features and response to open therapeutic trials. Movement Disorders, 1989, 4, 157-175. | 3.9 | 139 |
| 26 | The homeodomain transcription factor Pitx3 facilitates differentiation of mouse embryonic stem cells into AHD2-expressing dopaminergic neurons. Molecular and Cellular Neurosciences, 2005, 28, 241-252. | 2.2 | 138 |
| 27 | Genetic selection of sox1GFPâ€expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. Journal of Neurochemistry, 2006, 97, 1467-1480. | 3.9 | 137 |
| 28 | Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5108-5117. | 7.1 | 136 |
| 29 | Impact of the <scp>COVID</scp>â€19 Pandemic on Parkinson's Disease and Movement Disorders. Movement Disorders, 2020, 35, 711-715. | 3.9 | 134 |
| 30 | Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology, 2015, 84, 415-420. | 1.1 | 132 |
| 31 | Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Movement Disorders, 2018, 33, 282-288. | 3.9 | 122 |
| 32 | Double Transduction with GTP Cyclohydrolase I and Tyrosine Hydroxylase Is Necessary for Spontaneous Synthesis ofl-DOPA by Primary Fibroblasts. Journal of Neuroscience, 1996, 16, 4449-4456. | 3.6 | 112 |
| 33 | The Selective Toxicity of 1-Methyl-4-phenylpyridinium to Dopaminergic Neurons: The Role of Mitochondrial Complex I and Reactive Oxygen Species Revisited. Molecular Pharmacology, 2000, 58, 271-278. | 2.3 | 103 |
| 34 | Stromal Cell-Derived Inducing Activity, Nurr1, and Signaling Molecules Synergistically Induce Dopaminergic Neurons from Mouse Embryonic Stem Cells. Stem Cells, 2006, 24, 557-567. | 3.2 | 97 |
| 35 | A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. Journal of Neurosurgery, 2008, 109, 405-409. | 1.6 | 90 |
| 36 | Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Human Molecular Genetics, 2007, 16, 2900-2910. | 2.9 | 89 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Tetrahydrobiopterin Scavenges Superoxide in Dopaminergic Neurons. Journal of Biological Chemistry, 2001, 276, 34402-34407. | 3.4 | 86 |
| 38 | High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 179. | 5.2 | 86 |
| 39 | Effects of Low to Moderate Acute Doses of Pramipexole on Impulsivity and Cognition in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2008, 28, 45-51. | 1.4 | 85 |
| 40 | Dopamineâ€dependent motor learning: Insight into levodopa's longâ€duration response. Annals of Neurology, 2010, 67, 639-647. | 5.3 | 85 |
| 41 | Regulation of dopamine production by genetically modified primary fibroblasts. Journal of Neuroscience, 1993, 13, 5203-5211. | 3.6 | 84 |
| 42 | Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1015-1017. | 1.9 | 81 |
| 43 | Pink1 deficiency attenuates astrocyte proliferation through mitochondrial dysfunction, reduced akt and increased p38 mapk activation, and downregulation of egfr. Glia, 2013, 61, 800-812. | 4.9 | 81 |
| 44 | SMPD1 mutations, activity, and Î±â€synuclein accumulation in Parkinson's disease. Movement Disorders, 2019, 34, 526-535. | 3.9 | 81 |
| 45 | The Role of Glutathione in Dopaminergic Neuronal Survival. Journal of Neurochemistry, 1997, 69, 1850-1858. | 3.9 | 80 |
| 46 | Î±-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinsonâ€™s disease from multiple system atrophy. Acta Neuropathologica, 2021, 142, 495-511. | 7.7 | 80 |
| 47 | Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathologica, 2013, 126, 671-682. | 7.7 | 76 |
| 48 | Phosphorylated Î±-synuclein in Parkinsonâ€™s disease: correlation depends on disease severity. Acta Neuropathologica Communications, 2015, 3, 7. | 5.2 | 74 |
| 49 | Brain-derived neurotrophic factor-transduced fibroblasts: Production of BDNF and effects of grafting to the adult rat brain. Journal of Comparative Neurology, 1995, 354, 361-376. | 1.6 | 71 |
| 50 | Neural Precursors Derived from Embryonic Stem Cells, but Not Those from Fetal Ventral Mesencephalon, Maintain the Potential to Differentiate into Dopaminergic Neurons After Expansion In Vitro. Stem Cells, 2006, 24, 1583-1593. | 3.2 | 70 |
| 51 | Elevated GM3 plasma concentration in idiopathic Parkinsonâ€™s disease: A lipidomic analysis. PLoS ONE, 2017, 12, e0172348. | 2.5 | 69 |
| 52 | Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons. Journal of Neurochemistry, 2007, 104, 071018045431005-???. | 3.9 | 68 |
| 53 | Striatal Cholinergic Cell Ablation Attenuates l-DOPA Induced Dyskinesia in Parkinsonian Mice. Journal of Neuroscience, 2014, 34, 3090-3094. | 3.6 | 68 |
| 54 | The role of neuroplasticity in dopaminergic therapy for Parkinson disease. Nature Reviews Neurology, 2013, 9, 248-256. | 10.1 | 67 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Distinct Mechanisms of Neurodegeneration Induced by Chronic Complex I Inhibition in Dopaminergic and Non-dopaminergic Cells. Journal of Biological Chemistry, 2004, 279, 51783-51792. | 3.4 | 63 |
| 56 | Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: An analysis of the PPMI cohort. Parkinsonism and Related Disorders, 2018, 51, 49-54. | 2.2 | 61 |
| 57 | Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinsonâ€™s disease. Neurobiology of Disease, 2007, 27, 11-23. | 4.4 | 59 |
| 58 | Decreased Coenzyme Q10 Levels in Multiple System Atrophy Cerebellum. Journal of Neuropathology and Experimental Neurology, 2016, 75, 663-672. | 1.7 | 57 |
| 59 | Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 989-994. | 1.9 | 56 |
| 60 | Alpha galactosidase A activity in Parkinson's disease. Neurobiology of Disease, 2018, 112, 85-90. | 4.4 | 56 |
| 61 | In VivoL-DOPA Production by Genetically Modified Primary Rat Fibroblast or 9L Gliosarcoma Cell Grafts via Coexpression of GTPcyclohydrolase I with Tyrosine Hydroxylase. Experimental Neurology, 1998, 151, 249-264. | 4.1 | 53 |
| 62 | Mitophagy deficiency increases NLRP3 to induce brown fat dysfunction in mice. Autophagy, 2021, 17, 1205-1221. | 9.1 | 53 |
| 63 | Role of Aromatic <scp>l</scp>â€Amino Acid Decarboxylase for Dopamine Replacement by Genetically Modified Fibroblasts in a Rat Model of Parkinson's Disease. Journal of Neurochemistry, 1997, 69, 2055-2063. | 3.9 | 49 |
| 64 | Dopamine neuron glutamate cotransmission evokes a delayed excitation in lateral dorsal striatal cholinergic interneurons. ELife, 2018, 7, . | 6.0 | 49 |
| 65 | Letters to the editor. Movement Disorders, 1990, 5, 352-355. | 3.9 | 48 |
| 66 | Deduced amino acid sequence of bovine aromatic l-amino acid decarboxylase: homology to other decarboxylases. Molecular Brain Research, 1990, 8, 83-87. | 2.3 | 48 |
| 67 | Unilateral globus pallidus internus stimulation improves delayed onset post-traumatic cervical dystonia with an ipsilateral focal basal ganglia lesion. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 588-590. | 1.9 | 48 |
| 68 | The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Movement Disorders, 2016, 31, 924-932. | 3.9 | 48 |
| 69 | The antioxidant Trolox helps recovery from the familial Parkinson's disease-specific mitochondrial deficits caused by PINK1- and DJ-1-deficiency in dopaminergic neuronal cells. Mitochondrion, 2011, 11, 707-715. | 3.4 | 47 |
| 70 | Frequency of GBA Variants in Autopsyâ€proven Multiple System Atrophy. Movement Disorders Clinical Practice, 2017, 4, 574-581. | 1.5 | 47 |
| 71 | Vesicular Monoamine Transporter-2 and Aromaticl-Amino Acid Decarboxylase Enhance Dopamine Delivery afterl-3,4-Dihydroxyphenylalanine Administration in Parkinsonian Rats. Journal of Neuroscience, 1999, 19, 3266-3274. | 3.6 | 46 |
| 72 | CSF Î²-amyloid <sub>42</sub> and risk of freezing of gait in early Parkinson disease. Neurology, 2019, 92, e40-e47. | 1.1 | 45 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Balancing the basal ganglia circuitry: A possible new role for dopamine D2 receptors in health and disease. Movement Disorders, 2015, 30, 895-903. | 3.9 | 43 |
| 74 | A case of parkinsonism following striatal lacunar infarction.. Journal of Neurology, Neurosurgery and Psychiatry, 1986, 49, 1087-1088. | 1.9 | 41 |
| 75 | Preferential Resistance of Dopaminergic Neurons to the Toxicity of Glutathione Depletion Is Independent of Cellular Glutathione Peroxidase and Is Mediated by Tetrahydrobiopterin. Journal of Neurochemistry, 2002, 74, 2305-2314. | 3.9 | 41 |
| 76 | Cellular replacement therapy for neurologic disorders: potential of genetically engineered cells. Journal of Cellular Biochemistry, 1991, 45, 252-257. | 2.6 | 40 |
| 77 | A rapid Î±â€synuclein seed assay of Parkinsonâ€™s disease CSF panel shows high diagnostic accuracy. Annals of Clinical and Translational Neurology, 2021, 8, 374-384. | 3.7 | 40 |
| 78 | Structure of the Rat Aromatic L-Amino Acid Decarboxylase Gene: Evidence for an Alternative Promoter Usage. Journal of Neurochemistry, 1993, 60, 1058-1064. | 3.9 | 38 |
| 79 | Loss of PINK1 Attenuates HIF-1Î± Induction by Preventing 4E-BP1-Dependent Switch in Protein Translation under Hypoxia. Journal of Neuroscience, 2014, 34, 3079-3089. | 3.6 | 37 |
| 80 | Enhanced histamine H2 excitation of striatal cholinergic interneurons in l-DOPA-induced dyskinesia. Neurobiology of Disease, 2015, 76, 67-76. | 4.4 | 37 |
| 81 | Impact of the <scp>COVID</scp>â€19 Pandemic on Parkinson's Disease and Movement Disorders. Movement Disorders Clinical Practice, 2020, 7, 357-360. | 1.5 | 37 |
| 82 | SCARB2 variants and glucocerebrosidase activity in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2016, 2, . | 5.3 | 36 |
| 83 | Regulation of the Noradrenaline Neurotransmitter Phenotype by the Transcription Factor AP-2Î². Journal of Biological Chemistry, 2008, 283, 16860-16867. | 3.4 | 35 |
| 84 | Adaptation of Stability during Perturbed Walking in Parkinsonâ€™s Disease. Scientific Reports, 2017, 7, 17875. | 3.3 | 33 |
| 85 | DOPA-decarboxylation in the striata of rats with unilateral substantia nigra lesions. Neuroscience Letters, 1992, 147, 53-57. | 2.1 | 32 |
| 86 | The surfactant poloxamer-188 protects against glutamate toxicity in the rat brain. NeuroReport, 2004, 15, 171-174. | 1.2 | 32 |
| 87 | Alterations in the intrinsic properties of striatal cholinergic interneurons after dopamine lesion and chronic L-DOPA. ELife, 2020, 9, . | 6.0 | 32 |
| 88 | Structural determinants of PINK1 topology and dual subcellular distribution. BMC Cell Biology, 2010, 11, 90. | 3.0 | 29 |
| 89 | Activity enhances dopaminergic long-duration response in Parkinson disease. Neurology, 2012, 78, 1146-1149. | 1.1 | 26 |
| 90 | Comparison of clinical features in pathologically confirmed PSP and MSA patients followed at a tertiary center. Npj Parkinson's Disease, 2015, 1, 15007. | 5.3 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Surfactant poloxamer 188â€"related decreases in inflammation and tissue damage after experimental brain injury in rats. Journal of Neurosurgery: Pediatrics, 2004, 101, 91-96. | 1.3 | 25 |
| 92 | Poloxamer 188 Volumetrically Decreases Neuronal Loss in the Rat in a Time-dependent Manner. Neurosurgery, 2004, 55, 943-949. | 1.1 | 25 |
| 93 | Elevated In Vitro Kinase Activity in Peripheral Blood Mononuclear Cells of <scp>Leucineâ€Rich</scp> Repeat Kinase 2 <scp>G2019S</scp> Carriers: A Novel <scp>Enzymeâ€Linked</scp> Immunosorbent Assayâ€"Based Method. Movement Disorders, 2020, 35, 2095-2100. | 3.9 | 24 |
| 94 | Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression. Movement Disorders, 2021, 36, 2444-2446. | 3.9 | 24 |
| 95 | Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology, 2018, 90, 74-82. | 1.1 | 23 |
| 96 | Neuroprotective effect of the surfactant poloxamer 188 in a model of intracranial hemorrhage in rats. Journal of Neurosurgery: Pediatrics, 2007, 106, 36-40. | 1.3 | 21 |
| 97 | COVID-19 Vaccination for Persons with Parkinsonâ€™s Disease: Light at the End of the Tunnel?. Journal of Parkinson's Disease, 2021, 11, 3-8. | 2.8 | 21 |
| 98 | The Localization and Functional Contribution of Striatal Aromatic L-Amino Acid Decarboxylase to L-3,4-Dihydroxyphenylalanine Decarboxylation in Rodent Parkinsonian Models. Cell Transplantation, 2000, 9, 567-576. | 2.5 | 20 |
| 99 | Identification and Treatment of Cervical and Oromandibular Dystonia in Acutely Brain-Injured Patients. Neurocritical Care, 2005, 3, 139-145. | 2.4 | 20 |
| 100 | Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism and Related Disorders, 2019, 65, 178-183. | 2.2 | 20 |
| 101 | The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations. Experimental Neurology, 2003, 184, 304-312. | 4.1 | 18 |
| 102 | MPTP administration in mice changes the ratio of splice isoforms of fosB and rgs9. Brain Research, 2007, 1182, 1-10. | 2.2 | 18 |
| 103 | Letters to the editor. Movement Disorders, 1990, 5, 178-183. | 3.9 | 16 |
| 104 | <scp>mTOR</scp> Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Futility Trial and 1â€Year Biomarker Longitudinal Analysis. Movement Disorders, 2022, 37, 778-789. | 3.9 | 16 |
| 105 | Discussion of Research Priorities for Gait Disorders in Parkinson's Disease. Movement Disorders, 2022, 37, 253-263. | 3.9 | 16 |
| 106 | Transcription factor AP-2Î² regulates the neurotransmitter phenotype and maturation of chromaffin cells. Molecular and Cellular Neurosciences, 2011, 46, 245-251. | 2.2 | 15 |
| 107 | Preferential resistance of dopaminergic neurons to glutathione depletion in a reconstituted nigrostriatal system. Brain Research, 2000, 873, 203-211. | 2.2 | 14 |
| 108 | Evoked transients of pH-sensitive fluorescent false neurotransmitter reveal dopamine hot spots in the globus pallidus. ELife, 2018, 7, . | 6.0 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Effects of repeated waist-pull perturbations on gait stability in subjects with cerebellar ataxia. Journal of NeuroEngineering and Rehabilitation, 2019, 16, 50. | 4.6 | 10 |
| 110 | DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN. Neurology, 2014, 82, 636-637. | 1.1 | 9 |
| 111 | Parkinson's Disease Biomarkers: Resources for Discovery and Validation. Neuropsychopharmacology, 2014, 39, 241-242. | 5.4 | 8 |
| 112 | A site-specific mutation of tyrosine hydroxylase reduces feedback inhibition by dopamine in genetically modified cells grafted in parkinsonian rats. Journal of Neurochemistry, 2002, 83, 141-149. | 3.9 | 7 |
| 113 | Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology, 2012, 79, 1744-1744. | 1.1 | 7 |
| 114 | Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology, 2015, 85, 557-557. | 1.1 | 7 |
| 115 | Genetic Modification of Cells with Retrovirus Vectors for Grafting into the Central Nervous System. , 1995, , 211-237. | | 7 |
| 116 | Reversibility of Tardive Dyskinesia Syndrome. Tremor and Other Hyperkinetic Movements, 2020, 4, 282. | 2.0 | 7 |
| 117 | Potential of gene therapy for pediatric neurotransmitter diseases: Lessons from Parkinson's disease. Annals of Neurology, 2003, 54, S103-S109. | 5.3 | 6 |
| 118 | Exercise Reverses Dysregulation of T-Cell-Related Function in Blood Leukocytes of Patients With Parkinson's Disease. Frontiers in Neurology, 2020, 10, 1389. | 2.4 | 6 |
| 119 | Case 1, 1989: Juvenile-onset parkinsonism, dystonia, and pyramidal tract signs. Movement Disorders, 1989, 4, 363-370. | 3.9 | 5 |
| 120 | Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Movement Disorders, 2015, 30, 1862-1869. | 3.9 | 5 |
| 121 | <scp>C</scp>omments on the recent viewpoint article on lowâ€frequency deep brain stimulation for <scp>P</scp>arkinson's disease. Movement Disorders, 2017, 32, 176-176. | 3.9 | 5 |
| 122 | Intracerebral grafting in the dopaminergic system: issues and controversy. Current Opinion in Neurobiology, 1991, 1, 414-419. | 4.2 | 3 |
| 123 | Neuroprotective Therapy in Parkinson's Disease: Current Status and New Directions from | | |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Dopamine betaâ€hydroxylase activity in cerebrospinal fluid of idiopathic torsion dystonia. Neurology, 1990, 40, 1626-1626. | 1.1 | 3 |
| 128 | Reversibility of tardive dyskinesia syndrome. Tremor and Other Hyperkinetic Movements, 2014, 4, 282. | 2.0 | 3 |
| 129 | Association of Low Lysosomal Enzymes Activity With Brain Arterial Dilatation. Stroke, 2018, 49, 1977-1980. | 2.0 | 2 |
| 130 | Gene therapy for Parkinsonâ€™s disease: review and update. Expert Opinion on Investigational Drugs, 1999, 8, 1551-1564. | 4.1 | 1 |
| 131 | Reply To: <scp>D</scp>etection of <scp>A</scp>lphaâ€<scp>S</scp>ynuclein in <scp>S</scp>aliva: <scp>T</scp>he <scp>I</scp>mportance of <scp>P</scp>reanalytical <scp>A</scp>ssessment. Movement Disorders, 2018, 33, 1031-1031. | 3.9 | 1 |
| 132 | Trophic factor delivery by gene therapy. , 0, , 532-547. | | 0 |
| 133 | Biomarkers in neuropsychiatric diseases. Neurobiology of Disease, 2009, 35, 115-116. | 4.4 | 0 |
| 134 | Posters presentation selected for the blue ribbon session at the annual meeting of the Parkinson's disease and movement disorders society (Hong Kong, October, 2018).. Movement Disorders, 2018, 33, 1977-1991. | 3.9 | 0 |
| 135 | Synthes Award for Resident Research in Brain and Craniofacial Injury: poloxamer 188 volumetrically decreases neuron loss in the rat model of excitotoxicity in a time-dependent manner. Clinical Neurosurgery, 2003, 50, 374-81. | 0.2 | 0 |
| 136 | Reply to: â€œLetter on DiscussionÂof Gait Researchâ€• Movement Disorders, 2022, 37, 1328-1328. | 3.9 | 0 |